VivoSeq
0

Pipeline Programs

2

Active Trials

1

Companies Involved

NPC is an early-stage landscape with 0 programs across 1 company. The most active players are Nobelpharma.

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

88/100

Attrition Rate

8/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

12

clinical trials

Completed7 · 58%
Recruiting2 · 17%
Terminated1 · 8%
Available1 · 8%
Unknown status1 · 8%

Trial Activity

12 trials

Optimization of Cervical Nodal CTV for Early and Medium Stage NPC
Recruiting··Phase 3·NCT05145660·414 enrolled
LMP1- and LMP2-Specific CTLs to Patients With EBV-Positive NPC (NATELLA)
Completed··Phase 1·NCT00516087·23 enrolled
Investigation of Arrhythmogenic Effect of NPC-15 (NPC-15-7)
Completed·NNobelpharma·Phase 1·NCT03475459·12 enrolled
VTS-270 to Treat Niemann-Pick Type C1 (NPC1) Disease
Completed·MMandos LLC·Phase 2/3·NCT02534844·56 enrolled
NPC - AXEL Study : Axitinib-Avelumab
Completed··Phase 2·NCT04562441·13 enrolled
NPC-12G Gel 0.2% Sirolimus PK Bridging Study
Completed·NNobelpharma·Phase 1·NCT03972462·12 enrolled
Adrabetadex to Treat Niemann-Pick Type C1 (NPC1) Disease
Terminated·MMandos LLC·Phase 2/3·NCT04958642·66 enrolled
Study of DC-CIK to Treat NPC
Unknown status·GGuangxi Medical University·Phase 2·NCT01821495·100 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)